Strength of patient cohorts and biobanks for cardiomyopathy research

[1]  M. V. van Slegtenhorst,et al.  Effect of body surface area and gender on wall thickness thresholds in hypertrophic cardiomyopathy , 2019, Netherlands Heart Journal.

[2]  B. Brundel,et al.  Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy , 2019, Cells.

[3]  N. Sattar,et al.  Higher Body Mass Index in Adolescence Predicts Cardiomyopathy Risk in Midlife , 2019, Circulation.

[4]  A. Wilde,et al.  Mortality Risk Associated With Truncating Founder Mutations in Titin. , 2019, Circulation. Genomic and precision medicine.

[5]  M. Michels,et al.  Sex differences in hypertrophic cardiomyopathy: new insights , 2019, Current opinion in cardiology.

[6]  Y. Pinto,et al.  Relevance of Titin Missense and Non-Frameshifting Insertions/Deletions Variants in Dilated Cardiomyopathy , 2019, Scientific Reports.

[7]  M. Alders,et al.  Large next-generation sequencing gene panels in genetic heart disease: yield of pathogenic variants and variants of unknown significance , 2019, Netherlands Heart Journal.

[8]  A. van Rossum,et al.  Extra energy for hearts with a genetic defect: ENERGY trial , 2019, Netherlands Heart Journal.

[9]  J. van der Velden,et al.  Cardiac Disorders and Pathophysiology of Sarcomeric Proteins. , 2019, Physiological reviews.

[10]  E. Ashley,et al.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. , 2020, JAMA cardiology.

[11]  Matthew J. Daniels,et al.  Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield , 2018, Genetics in Medicine.

[12]  N. Sebire,et al.  Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy , 2018, Circulation. Genomic and precision medicine.

[13]  M. Götte,et al.  Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. , 2018, Journal of molecular and cellular cardiology.

[14]  B. Brundel,et al.  Untying the knot: protein quality control in inherited cardiomyopathies , 2018, Pflügers Archiv - European Journal of Physiology.

[15]  M. Mayr,et al.  Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology , 2018, Cardiovascular research.

[16]  K. Margulies,et al.  Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure , 2018, Nature Medicine.

[17]  C. Poggesi,et al.  Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy , 2018, Circulation. Heart failure.

[18]  B. Brenner,et al.  Burst-Like Transcription of Mutant and Wildtype MYH7-Alleles as Possible Origin of Cell-to-Cell Contractile Imbalance in Hypertrophic Cardiomyopathy , 2018, Front. Physiol..

[19]  S. Heymans,et al.  Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias , 2018, European heart journal.

[20]  A. Lammertsma,et al.  Disease Stage–Dependent Changes in Cardiac Contractile Performance and Oxygen Utilization Underlie Reduced Myocardial Efficiency in Human Inherited Hypertrophic Cardiomyopathy , 2017, Circulation. Cardiovascular imaging.

[21]  R. D. de Boer,et al.  Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. , 2016, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[22]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[23]  B. Brenner,et al.  Hypertrophic Cardiomyopathy: Cell-to-Cell Imbalance in Gene Expression and Contraction Force as Trigger for Disease Phenotype Development. , 2016, Circulation research.

[24]  L. Carrier,et al.  Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. , 2016, Journal of molecular and cellular cardiology.

[25]  H. Ahmadzadeh,et al.  Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes , 2016, Science.

[26]  B. Brenner,et al.  Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development , 2014, Front. Physiol..

[27]  A. van Rossum,et al.  Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. , 2014, Cardiovascular research.

[28]  J. van der Velden,et al.  The physiological role of cardiac cytoskeleton and its alterations in heart failure. , 2014, Biochimica et biophysica acta.

[29]  Y. Pinto,et al.  Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience , 2013, European journal of heart failure.

[30]  R. Hauer,et al.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[31]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[32]  A. Blamire,et al.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.

[33]  H. Watkins,et al.  Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. , 2003, Trends in genetics : TIG.

[34]  D. Kass,et al.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.